Appendix 4C - Quarterly Cashflow Statement
Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2014.
Starpharma raises $3.5M through SPP following $18M Placement
Starpharma today announced it has raised a total of approximately $21.5 million following the closing of its Share Purchase Plan (SPP) on Wednesday 29 October 2014. The Company raised approximately $3.5 million from existing eligible shareholders through the SPP. The SPP followed the Company’s recent $18 million share placement to sophisticated and institutional investors, which was significantly oversubscribed.
Starpharma receives $4.2 million R&D tax incentive refund
Starpharma today announced it has received the anticipated $4.2M of R&D tax incentive refund relating to FY14 expenditures.
VivaGel® condom now available in Australian stores
Starpharma is pleased to announce that the Company has been notified by its commercial partner, Ansell (ASX:ANN), that the VivaGel® condom is now available for purchase from Woolworths stores in Australia under Ansell’s brand, LifeStyles® Dual Protect™.
Starpharma Boardroom Radio Interview
Starpharma is pleased to provide investors with the opportunity to listen to an audio interview with Chief Executive Officer Dr Jackie Fairley on Boardroom Radio (BRR).
Extension of Share Purchase Plan
Starpharma advises that it has extended the closing date of its share purchase plan (SPP) following the release today of preliminary positive DEP™ docetaxel pharmacokinetic (PK) findings from its Phase I clinical trial.
DEP™ docetaxel shows intended longer duration and increased exposure
Starpharma today announced it has completed preliminary analyses of the pharmacokinetics (PK) of DEP™ docetaxel from the ongoing Phase 1 human clinical trial using results from the first cycle of dosing for several patients.
Starpharma to present at US Drug Delivery Conference
Starpharma today announced that it will be presenting its DEP™ platform at the 4th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston this week.
Shareholder Update October 2014
In this Issue:
› Encouraging clinical data for DEP™ docetaxel
› VivaGel® condom approved for sale in Australia – Launch imminent
› VivaGel® for BV: SPA agreement for Phase 3 and commercialisation activities for Symptomatic Relief
› Starpharma completes $18M Placement; launches $5M SPP
› Dendrimer-enhanced agrochemicals
› Full Year 2014 annual financial results
Download: Shareholder Update October 2014 (pdf file, 1MB)
VivaGel® condom approved for sale with launch imminent
Starpharma today announced the inclusion of the VivaGel® condom in the Australian Register of Therapeutic Goods (ARTG), the final step ahead of market launch in Australia.
Starpharma’s partner in innovating and bringing this product to market, Ansell (ASX:ANN), has made the necessary preparations, including manufacture of launch supplies, and will launch the VivaGel® condom under the LifeStyles® Dual Protect™ name in Australian retail outlets, including Woolworths stores around the country, during October.